RecruitingNot ApplicableNCT06899399

Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis


Sponsor

Beijing Tiantan Hospital

Enrollment

982 participants

Start Date

Oct 18, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Inclusion Criteria7

  • Age 40-80 years
  • Severe asymptomatic internal carotid artery stenosis (70-99%) confirmed by ultrasound/CTA/DSA
  • Contralateral ICA stenosis \<70%
  • No TIA/stroke related to target lesion in past 6 months
  • Declined carotid endarterectomy
  • Willing to complete 12-month follow-up
  • Signed informed consent by participant/legal representative

Exclusion Criteria29

  • symptomatic internal carotid artery stenosis in the past 6 months
  • Spontaneous intracranial hemorrhage in nearly one year
  • Patients with larger intracranial aneurysms (diameter \>5 mm) who cannot undergo prior or concurrent treatment
  • Chronic occlusion without obvious symptoms of cerebral ischemic attack
  • Patients with transient or permanent neurological deficit resulting from Neurological deficits mimicking TIA/stroke from TIA or stroke
  • Common carotid artery ostial lesion
  • Tandem lesions with severe stenosis of the ipsilateral intracranial artery
  • Patients with severe dementia
  • Internal carotid artery dissection
  • Internal carotid artery aneurysm
  • Myocardial infarction within 30 days
  • Ejection fraction \<30% or New York Heart Association (NYHA) functional class III or higher; unstable angina, characterized by angina at rest with electrocardiogram changes
  • Cardiogenic embolism, including left ventricular aneurysm, intraluminal filling defects, cardiomyopathy, aortic or mitral valve-prosthetic heart valve, calcified aortic stenosis, infective endocarditis
  • Mitral stenosis, atrial septal defect, atrial septal aneurysm or left chamber myxoma
  • Two or more proximal or main coronary artery stenosis 70%, untreated or recanable
  • Platelets \<5 \* 104 / uL, INR\> 1.5, bleeding time\> 1min or heparin-related thrombocytopenia; heparin is a contraindication to antiplatelet drugs; coagulopathy
  • Poor controlled diabetes mellitus, fasting blood glucose\> 22 mmol/L and ketone body\>+2
  • Malignant tumor or respiratory insufficiency, and a life expectancy of \<5 years
  • Severe liver and kidney function impairment, ALT\> 3 times the upper limit of normal value or AST\> 3 times the upper limit of normal value, blood creatinine increase\> 2 times the upper limit of normal value
  • Contrast allergy
  • Other general anesthesia operations are required during the same period
  • Pregnant or lactating women
  • The patient does not attend the clinical trial of other drug or medical device before enrollment
  • The investigator is not considered fit to participate in this clinical study
  • Type III aortic arch
  • Severe angulation or tortuosity (≥90 degrees) of the common carotid artery or innominate artery that prevents safe and rapid placement of a guiding catheter or long sheath
  • Severe angulation or tortuosity of the internal carotid artery that prevents safe deployment of an embolic protection device or stent. Severe tortuosity is defined as the presence of two or more angles ≥90 degrees within 4 cm of the stenotic lesion
  • Stenosis of the beginning or proximal end of the common carotid artery, innominate artery, distal or intracranial segment of the internal carotid artery, and the stenosis degree is greater than that of the target stenosis
  • The stenotic lesion exhibits severe circumferential calcification, defined as calcification greater than 3 mm in thickness visible in orthogonal views during fluoroscopy. (Note: In elderly subjects aged ≥70 years, anatomical factors such as tortuosity, arch anatomy, and calcification must be assessed more carefully)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndovascular treatment

Participants will receive carotid artery stenting as the primary intervention. The procedure will be performed via femoral artery access (radial access allowed for anatomically challenging cases) with mandatory use of an embolic protection device (EPD). Stent selection and EPD type will be determined by the operator based on lesion characteristics. Pre-procedural dual antiplatelet therapy (DAPT: aspirin 100 mg/day + clopidogrel 75 mg/day) will be administered for ≥3-5 days. Post-procedural DAPT will continue for 3 months, transitioning to aspirin monotherapy (100 mg/day) thereafter. Statins and risk factor management (blood pressure、LDL-C, glycemic control) will align with standardized protocols.

DRUGBest medical treatment

Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance. Statin therapy and risk factor control targets (blood pressure, lipids, glucose, lifestyle) will mirror the experimental group. Both groups will undergo regular follow-up for adherence monitoring.


Locations(1)

Beijing Tiantan Hospital, Capital Medical University

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06899399